-
ABPI Website
-
Improving the UK's health data capability & the industry's access to data
- Industry use of Health Data Case Study Library
Industry use of Health Data Case Study Library
Explore our case studies library to understand how the pharmaceutical industry uses anonymised NHS data in research to understand the cause and progression of disease, to develop new medicines and evaluate the best care pathways for patients with different conditions.
Why the pharmaceutical industry needs NHS data to develop new medicines
To accompany the launch of the Industry Use of Health Data Case Study Library, ABPI Executive Director for Research and Innovation, Janet Valentine, explains why it is important for the pharmaceutical industry to access to anonymised NHS data for research to develop new safe and effective medicines that benefit patients in the UK and globally.
Global patterns in hip fractures: trends in occurrence, treatment, and survival - Amgen
Hip fractures relating to weak and brittle bones are a global public health concern, with over 10 million cases per year globally.
Do type 2 diabetes medicine trial results reflect the UK patient population? - Eli Lilly
Cardiovascular disease (CVD) is a leading cause of death and illness among individuals with type 2 diabetes (T2D).
Understanding the safety of the drug eliglustat over time for adults with Gaucher disease - Sanofi
Gaucher disease is a rare genetic condition where fatty substances build up in organs, like the liver, spleen and bones.
A thorough investigation of patient genetic data to improve treatments for specific conditions - UCB
Many causes of disease are associated with an individual’s genetic make-up and there is increasing interest in medical research to understand how our genes might influence our chances of getting a disease.